KALAMAZOO, Mich., June 21 /PRNewswire/ -- NanoMed Pharmaceuticals, Inc., an early-stage specialty pharmaceutical company dedicated to developing improved therapeutic and diagnostic products to treat or detect cancer and other serious diseases, announced today that it has hired Harry C. Ledebur, Jr., PhD. to serve as the company’s Vice President Research & Development, Chief Scientific Officer. Prior to joining NanoMed, Dr. Ledebur was Vice President, Operations & Scientific Affairs for Chromos Molecular Systems, Inc. where he was a member of Chromos’ Executive Committee and was responsible for all discovery and product development programs along with quality systems, regulatory affairs and site operations.
“I am extremely pleased to have the opportunity to partner with a research and development executive of Harry’s caliber,” said Stephen Benoit, NanoMed’s President and CEO. “His extensive experience in preclinical discovery research, product and business development within the biotechnology and pharmaceutical industries should prove to be a tremendous asset to NanoMed as we build our drug pipeline and forge strategic product development relationships,” Benoit added. NanoMed’s lead product is a nanoparticle formulation of an FDA-approved cancer drug used to treat adults diagnosed with acute myeloid leukemia. This lead product is expected to enter human clinical trials in 2008.
“NanoMed is an exciting company with an innovative nanotechnology platform for the rapid development of a diversified portfolio of therapeutic and diagnostic products,” said Dr. Ledebur. “I am thrilled to be joining the NanoMed team and to be given the opportunity to bring NanoMed’s products to market while helping to build a sustainable specialty pharmaceutical company,” Ledebur added.
Previously, Dr. Ledebur was Vice President of Research & Development and Discovery Programs for Caprion Pharmaceuticals Inc., as well as Program Head of the Antigen Presenting Cell Program at US-based Valentis, Inc. (formerly GeneMedicine, Inc.). He began his career at Boehringer Ingelheim Pharmaceuticals Inc. Dr. Ledebur received his Ph.D. in Molecular & Cell Biology from Pennsylvania State University and his B.Sc. in Biochemistry from The Ohio State University.
About NanoMed
NanoMed Pharmaceuticals(R), Inc. (www.nanomedpharm.com) is an early-stage specialty pharmaceutical company dedicated to developing improved therapeutic and diagnostic products to treat or detect cancer and other serious diseases. The company’s lead product is a nanoparticle formulation of an FDA-approved cancer drug used to treat adults diagnosed with acute myeloid leukemia. This lead product is being developed using Nanotemplate Engineering(TM), the company’s proprietary nanoparticle manufacturing technology used to formulate small molecules, peptides, proteins, plasmid DNA, and diagnostic agents. NanoMed is headquartered in Kalamazoo, Michigan.
NanoMed Pharmaceuticals, Inc.
CONTACT: Stephen Benoit, CEO of NanoMed Pharmaceuticals(R), Inc.,+1-269-488-8525, benoit@nanomedpharm.com
Web site: http://www.nanomedpharm.com/
